Literature DB >> 8723225

Major histocompatibility complex class I expression in oligodendrocytes induces hypomyelination in transgenic mice.

C Power1, P A Kong, B D Trapp.   

Abstract

Increased expression of MHC Class I occurs in the central nervous system in association with demyelinating diseases such as multiple sclerosis and experimental allergic encephalomyelitis. To determine if MHC Class I expression by oligodendrocytes induces white matter pathology, the MHC Class I gene was expressed in transgenic mice under the control of the myelin basic protein (MBP) promoter. These mice display a neurological phenotype at 21 days-of-age. We examined these mice at 1,3, and 12 weeks-of-age. MHC Class I was detected in the brains and spinal cords of transgenic mice but not in control mice. Class I was located in oligodendrocyte perikarya but not in myelin sheaths. The central nervous system of these transgenic mice was hypomyelinated and contained hypertrophic microglia and astrocytes. These observations establish that Class I expression by oligodendrocytes delays normal myelination but does not cause inflammatory demyelination. This hypomyelinating animal model is of potential use in studying the interactions between immunologically active molecules and remyelination in disorders of myelin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8723225     DOI: 10.1002/(SICI)1097-4547(19960415)44:2<165::AID-JNR9>3.0.CO;2-B

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  10 in total

Review 1.  The unfolded protein response in protein aggregating diseases.

Authors:  Alexander Gow; Ramaswamy Sharma
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

2.  On the occurrence of hypomyelination in a transgenic mouse model: a consequence of the myelin basic protein promoter?

Authors:  Stefanie Gaupp; Joseph Arezzo; Dipankar J Dutta; Gareth R John; Cedric S Raine
Journal:  J Neuropathol Exp Neurol       Date:  2011-12       Impact factor: 3.685

3.  Neutrophil infiltration, glial reaction, and neurological disease in transgenic mice expressing the chemokine N51/KC in oligodendrocytes.

Authors:  M Tani; M E Fuentes; J W Peterson; B D Trapp; S K Durham; J K Loy; R Bravo; R M Ransohoff; S A Lira
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

Review 4.  Transgenic mouse models of multiple sclerosis.

Authors:  Tanja Scheikl; Béatrice Pignolet; Lennart T Mars; Roland S Liblau
Journal:  Cell Mol Life Sci       Date:  2010-08-17       Impact factor: 9.261

Review 5.  Oligodendroglial response to the immune cytokine interferon gamma.

Authors:  B Popko; K D Baerwald
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

6.  The unfolded protein response modulates disease severity in Pelizaeus-Merzbacher disease.

Authors:  Cherie M Southwood; James Garbern; Wei Jiang; Alexander Gow
Journal:  Neuron       Date:  2002-11-14       Impact factor: 17.173

7.  Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease.

Authors:  A Gow; C M Southwood; R A Lazzarini
Journal:  J Cell Biol       Date:  1998-02-23       Impact factor: 10.539

8.  MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: Implications for virus biology, disease mechanisms and neuropathology.

Authors:  Zaikun Xu; Eugene L Asahchop; William G Branton; Benjamin B Gelman; Christopher Power; Tom C Hobman
Journal:  PLoS Pathog       Date:  2017-06-08       Impact factor: 6.823

Review 9.  The effects of interferon-gamma on the central nervous system.

Authors:  B Popko; J G Corbin; K D Baerwald; J Dupree; A M Garcia
Journal:  Mol Neurobiol       Date:  1997 Feb-Apr       Impact factor: 5.590

10.  Induction of class I antigen processing components in oligodendroglia and microglia during viral encephalomyelitis.

Authors:  Karen E Malone; Stephen A Stohlman; Chandran Ramakrishna; Wendy Macklin; Cornelia C Bergmann
Journal:  Glia       Date:  2008-03       Impact factor: 7.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.